Advertisement
help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 10, No. 9, 701-709, October 2005; doi:10.1634/theoncologist.10-9-701
© 2005 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chung, K. Y.
Right arrow Articles by Saltz, L. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chung, K. Y.
Right arrow Articles by Saltz, L. B.

Antibody-Based Therapies for Colorectal Cancer

Ki Young Chung, Leonard B. Saltz

Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA; Weill Medical College of Cornell University, New York, New York, USA

Key Words. Angiogenesis • Epidermal growth factor receptor • Monoclonal antibodies • Bevacizumab • Cetuximab

Correspondence: Ki Young Chung, M.D., Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA. Telephone: 212-639-6121; Fax: 646-422-2246; e-mail: chungk{at}mskcc.org

The recent successful development of novel monoclonal antibodies that target key components of biologic pathways has expanded the armamentarium of treatment options for patients with colorectal cancer. Two targets in particular–the process of new blood vessel development, or angiogenesis, and the epidermal growth factor receptor and its signaling pathway–are exploited by the newest monoclonal antibodies that are available for use in colorectal cancer patients. This clinical review focuses on the defining role of the two most clinically advanced novel agents, bevacizumab (Avastin®; Genentech, Inc., South San Francisco, CA, http://www.gene.com) and cetuximab (Erbitux®; ImClone Systems, Inc., New York, http://www.imclone.com), in colorectal cancer.




This article has been cited by other articles:


Home page
 Anticancer ResHome page
S. DEEN, O. L. GRIFFITH, H. MASOUDI, A. GOWN, S. J.M. JONES, and S. M. WISEMAN
Anaplastic Thyroid Carcinoma Exhibits Intratumoral Molecular Homogeneity for a Therapeutic Target Panel
Anticancer Res, July 1, 2009; 29(7): 2437 - 2444.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Debucquoy, K. Haustermans, A. Daemen, S. Aydin, L. Libbrecht, O. Gevaert, B. De Moor, S. Tejpar, W. H. McBride, F. Penninckx, et al.
Molecular Response to Cetuximab and Efficacy of Preoperative Cetuximab-Based Chemoradiation in Rectal Cancer
J. Clin. Oncol., June 10, 2009; 27(17): 2751 - 2757.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Maccalli, V. Di Cristanziano, V. Fodale, D. Corsi, G. D'Agostino, V. Petrangeli, L. Laurenti, S. Guida, A. Mazzocchi, F. Arienti, et al.
Induction of Both CD8+ and CD4+ T-Cell-Mediated Responses in Colorectal Cancer Patients by Colon Antigen-1
Clin. Cancer Res., November 15, 2008; 14(22): 7292 - 7303.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Prewett, D. S. Deevi, R. Bassi, F. Fan, L. M. Ellis, D. J. Hicklin, and J. R. Tonra
Tumors Established with Cell Lines Selected for Oxaliplatin Resistance Respond to Oxaliplatin if Combined with Cetuximab
Clin. Cancer Res., December 15, 2007; 13(24): 7432 - 7440.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J-P Machiels, C Sempoux, P Scalliet, J-C Coche, Y Humblet, E Van Cutsem, J Kerger, J-L Canon, M Peeters, S Aydin, et al.
Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer
Ann. Onc., April 1, 2007; 18(4): 738 - 744.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
K. K. Hahn, J. J. Wolff, and J. M. Kolesar
Pharmacogenetics and irinotecan therapy
Am. J. Health Syst. Pharm., November 15, 2006; 63(22): 2211 - 2217.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H.-J. Lenz, E. Van Cutsem, S. Khambata-Ford, R. J. Mayer, P. Gold, P. Stella, B. Mirtsching, A. L. Cohn, A. W. Pippas, N. Azarnia, et al.
Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines
J. Clin. Oncol., October 20, 2006; 24(30): 4914 - 4921.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Nagorsen and E. Thiel
Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer.
Clin. Cancer Res., May 15, 2006; 12(10): 3064 - 3069.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
V. R. Adams
Evolving role of antineoplastic agents in colorectal cancer
Am. J. Health Syst. Pharm., May 1, 2006; 63(9_Supplement_2): S4 - S11.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2005 by AlphaMed Press.
Advertisement